It has been demonstrated that DcR3 expression levels are correlated with lung cancer cell sensitivity to chemotherapy and that DcR3 interference may enhance lung cancer cell sensitivity to chemotherapy (10). This evidence concerns the gene TNFRSF6B and lung carcinoma.